Accelerating Therapeutic DiscoveryTM

Application Instructions

If you are interested in receiving support for a research project that falls into one of the categories listed on our Therapeutic Strategies, please follow the application instructions.

Click to download: Letter of Interest and Full Application Instructions

Thank you for your interest in ending the effects of COPD and liver disease caused by Alpha-1 Antitrypsin Deficiency.

Select the search type
  • Site
  • Web
Search

About The Alpha-1 Project

The Alpha-1 Project (TAP) is a wholly owned subsidiary of the Alpha-1 Foundation singularly focused on bridging the gap between clinical trials and commercialization of therapies for the elimination of Chronic Obstructive Pulmonary Disease (COPD) and liver disease caused by Alpha-1 Antitrypsin Deficiency (Alpha-1).

Learn More

Latest News

Inhibrx Announces Enrollment of First Patient in Phase 1 Study of INBRX-101, a Modified Recombinant Human AAT-Fc Fusion Protein
Posted on November 18, 2019
Arrowhead Pharmaceuticals Doses First Patient in SEQUOIA Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
Arrowhead Pharmaceuticals Inc., has dosed the first patient in SEQUOIA (AROAAT2001), a potentially pivotal Phase 2/3 clinical...
Posted on August 08, 2019

General Contact

The Alpha-1 Project

3300 Ponce de Leon Boulevard
Coral Gables, FL 33134
Phone: 305-648-9541
Toll-free: 888-920-0002
Fax: 305-441-2110
Email: info@thealpha-1project.com

The Alpha-1 Project Alpha-1 Antitrypsin Deficiency Therapeutic Strategies Clinical Trial Resources Progress Reports About Us Login
Copyright (c) 2021 The Alpha 1 Project All Rights Reserved | Terms Of Use | Privacy Statement
The Alpha-1 Project® is a registered trademark of the Alpha-1 Foundation, Inc.
Accelerating Therapeutic Discovery™ is a registered trademark of The Alpha-1 Foundation, Inc.
Website by IMI Software, Inc.